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Abstract 
Multiple sclerosis (MS) is an autoimmune neurodegenerative disease characterized by 
demyelination of the central nervous system (CNS). The exact cause of MS is still unknown; 
yet its incidence and prevalence rates are growing worldwide, making MS a significant public 
health challenge. The heterogeneous distribution of demyelination within and between MS 
patients translates in a complex and varied array of autonomic, motor, sensory and cognitive 
symptoms. Yet a unique aspect of MS is the highly prevalent (60-80%) temperature 
sensitivity of its sufferers, where neurological symptoms are temporarily exacerbated by 
environmental- or exercise-induced increases (or decreases) in body temperature. MS 
temperature sensitivity is primarily driven by temperature-dependent slowing or blocking of 
neural conduction within the CNS due to changes in internal (core) temperature; yet changes 
in skin temperature could also contribute to symptom exacerbation (e.g. during sunlight and 
warm ambient exposure). The impact of temperature sensitivity, and particularly of increases 
in core temperature, on autonomic (e.g. thermoregulatory/cardiovascular function) and motor 
symptoms (e.g. fatigue) is well described. However, less attention has been given to how 
increases (and decreases) in core and skin temperature affect sensory and cognitive 
symptoms. Furthermore, it remains uncertain whether changes in skin temperature alone 
could also trigger worsening of symptoms. Here we review the impact of temperature 
sensitivity on MS sensory and cognitive function and discuss additional factors (e.g. changes 
in skin temperature) that potentially contribute to temperature-induced worsening of 
symptoms in the absence of alteration in core temperature.  
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Introduction  
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous 
system (CNS) that causes progressive disability in the majority of patients. Inflammatory 
demyelination, i.e. the partial or complete loss of the myelin sheath that envelops nerve fibres 
within the CNS, underlies the chronic neurodegeneration that characterizes MS and the 
plethora of clinical signs and symptoms that accompany the disease [1].  
Variability in the location and degree of inflammatory demyelination within the CNS results 
in each patient experiencing a unique combination of symptoms. However, (temporary) 
symptom worsening following changes in body temperature (i.e. a combination of 
internal/core and external/skin temperatures), i.e. temperature sensitivity, is a common 
occurrence. As a result, MS patients experience significant challenges in maintaining 
appropriate physical activity levels and conducting normal working activities.  
The impact of temperature sensitivity and particularly of increases in internal/core 
temperature, on autonomic (e.g. thermoregulatory/cardiovascular function) and motor 
symptoms (e.g. fatigue) is well described. However, less attention has been given to the 
mechanisms by which increases (and decreases) in core and skin temperature modulate 
sensory and cognitive symptoms in MS. Furthermore, it remains uncertain whether changes in 
skin temperature alone can trigger worsening of symptoms.  
Here we review the impact of temperature sensitivity on MS sensory and cognitive function 
and discuss additional factors (e.g. changes in skin temperature) that potentially contribute to 
temperature-induced worsening of symptoms in the absence of alteration in core temperature. 
 
Pathophysiology of MS 
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The prevailing hypothesis about the pathophysiology of MS contends that the myelin sheath 
of CNS axons is targeted, and ultimately destroyed, by a macrophage mediated, adaptive-
immune cell driven autoimmune process. While the factors that initiate CNS autoimmunity 
are still unclear, the resulting inflammation and loss of myelin that characterize the acute MS 
lesion are known to occur through the operation of lymphocytes, macrophages, microglial 
cells and potentially astrocytes [2-7].  
Myelin is necessary in facilitating fast conduction velocities of neural inputs within the CNS. 
Accordingly, inflammation of the CNS and the related lesions that occur in the white and grey 
matter across the CNS of MS patients, result in slowing and/or blocking of neural 
transmission within the CNS (Fig. 1) [8,9].  
The appearance and location of new lesions in MS is unpredictable and vary within the CNS 
[10]. Brain lesions, as identified via magnetic resonance imaging (MRI), can occur at both 
cortical and subcortical sites.  The periventricular region, cerebellum, brainstem, and optic 
pathways are frequently affected [11,12]. Hypothalamic lesions, which may be at the root of 
autonomic, endocrine and metabolic-related dysfunction observed in some patients with MS, 
are common [13]. While less prevalent than brain lesions, spinal lesions, particularly within 
the cervical cord, are also common [14]. Interestingly, re-myelination has been observed to 
occur in many MS lesions, yet this varies significantly between individuals [15] and is an 
inadequate or not a completely restorative process.  
 
Multiple sclerosis incidence and prevalence 
Historically, clinical signs of MS were first observed in some patients in the early 19th 
century, when Robert Carswell and Jean Cruveilhier described the histopathology of the 
disease and the concept of neurodegeneration in the brain [16,17]. Later in the 19th century, 
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Jean-Martin Charcot synthesized the clinical and neuropathology features of MS as a disease 
of the CNS. Thereafter, MS plaques and lesions were observed post mortem [18].  
Signs and symptoms of MS may appear from childhood to late adulthood, with the average 
age for diagnosis being ~30 years old [12].  
The estimated number of people with MS recorded in 2008 was reported to be about 2.1 
million people worldwide. In 2013 this number had increased to 2.3 million [19]. Incidence 
rates vary widely, depending on geographic location and other factors, and fluctuate between 
5 and 12 new cases per 100,000 people every year [20]. The disease has been shown to be 
more prevalent in females than in males [20]. Geographically, MS is generally reported to be 
less prevalent in areas close to the equator. [21]. In relation to ethnic variability, Caucasians 
have a higher probability of being diagnosed with MS in comparison to other individuals [21].  
MS can be classified into three types based on its clinical course: relapsing-remitting (RRMS) 
(85%) [18]; secondary-progressive (SPMS) [19]; primary-progressive (PPMS) [20-28] [Table 
1]. RRMS is the most prevalent MS subtype and more common in females with younger 
disease onset. [20]. SPMS is characterized by gradual deterioration of clinical symptoms that 
take place between or irrespective of relapses [24]. PPMS patients encounter disability 
without experiencing relapses or remissions. Despite a paucity of new lesions relative to other 
disease subtypes, persistently accelerated brain atrophy is typical [24].  
 
Symptomatology of MS 
Symptomatic axonal dysfunction occurs in eloquently distributed MS lesions, with individual 
clinical variations primarily reflecting the heterogeneity of lesion location, particularly in 
patients with early, relapsing disease.   It is therefore common for patients to perceive their 
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experience of MS and related symptomatology as “unique” when compared to other patients.  
Despite this variability, many MS patients experience an array of common symptoms [1,29]. 
Overall, these commonly shared symptoms can be categorized as motor, sensory, and 
cognitive. Autonomic nervous system dysfunction is also reported in MS patients and has 
been extensively reviewed elsewhere [1,30,31].  
 
Motor symptoms 
Motor deficits are frequently reported in MS (Fig. 2). Spasticity (where disinhibited 
physiological reflexes in the spinal cord can produce involuntary, stiff and painful muscle 
movements in the extremities) occurs in 80% of the patients [32,33]. Similarly, 75% of the 
patients report walking difficulties and 50% accidental injuries due to frequent falls [32]. In 
turn, those symptoms result in many MS patients (i.e. ~50%) ultimately requiring walking 
aids or wheelchairs [34]. Other motor symptoms include: upper limb weakness, balance 
impairment, discoordination, difficulty swallowing, poor articulation, grip impairment, and 
tremor in the extremities [22,35-41].  
Fatigue is a prevalent sym tom in people with MS. 53 to 97% of the MS patients report 
fatigue [34,42,43] and 69% report that this is the MS symptom that causes them the most 
distress [44]. Even though the experience of fatigue in MS is subjective and can occur in early 
disease patients, motor symptoms such as body weakness, incoordination, tremor in the 
extremities and exhaustion seem to play an essential role in its occurrence [45]. Based on the 
symptomatology, it is suggested that fatigue in MS is the outcome of excess axonal activity in 
the demyelinated CNS [46,47]. Notwithstanding, MS fatigue is a multifactorial phenomenon, 
and its subjective character in self-reported questionnaires is difficult to evaluate.  
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MS sufferers may also suffer from a cerebellar sign called dysmetria, frequently accompanied 
by ataxia, tremor and uncoordinated movements in the extremities. Lesions in the cerebellum 
play an essential part in the manifestation of symptoms, especially for limb coordination and 
motor performance [48]. 
Finally, eye movement disorders, such as internuclear ophthalmoplegia resulting from lesions 
in the medial longitudinal fasciculus in the brainstem [49,50] and nystagmus [49,51], are 
frequent in MS [34]. Poor visual acuity due to optic neuritis, and double vision due to 
brainstem lesions [52], also impact patients’ movement and balance [52].  
It is important to note that while the majority of motor symptoms arise as a direct 
consequence of the disease, patients may also experience motor disturbances as side effects 
from medications such as corticosteroids (used to treat relapse symptoms) and 
anticholinergics (used to assist with urinary urgency and incontinence). These drug categories 
can cause fatigue, difficulty in breathing and eye disorders [53]; and are reported to affect 
pharyngeal sensations in patients that can lead to difficulties in swallowing when eating 
(dysphagia) [54] 
 
Sensory symptoms 
Sensory abnormalities and pain are observed in 80% of patients with MS, with significant 
consequences for quality of life (Figure 2) [55,56]. Like most symptoms, sensory deficits 
seem to correlate with the number and location of the lesions in the CNS [57-60]. 
Central or musculoskeletal pain is reported by 90% of patients during MS progression and is 
associated with plaques and lesions along the spinothalamic pathways [61]. Approximately 
50% of MS patients experience pain and altered sensations such as tingling and numbness 
with higher incidence in their extremities, back and head (~65%) [61].  
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Allodynia and paraesthesia are also often reported sensory impairments in MS. 
Approximately 8% of MS patients experience mechanical allodynia, a painful sensation that 
comes with the light touch of a stimulus on the skin; ~35% of the MS patients experience cold 
allodynia when a cold stimulus touches the skin [61]. 40-80% of the patients claim that 
paraesthesia symptoms (tingling) affect their daily life, especially when they become 
persistent [56,62]. Furthermore, some people with MS may experience dysaesthesia and 
Lhermitte’s phenomenon as a result of spinal cord demyelination [63,64]. Dysaesthesia is 
manifested as an intense pain of pins and needles and burning sensation, usually present in the 
extremities [58,65]. Lhermitte’s sign is an electrical shock sensation occurring with neck 
flexion in 55-70% of patients with MS, often extending from the neck to the spine and in 
some patients involving the limbs [66,67]. 
Patients with MS can also experience trigeminal neuralgia, which manifests as sudden 
episodes of pain, burning sensation, itching in the areas covered by the trigeminal nerve on 
one side of the face [68,69]. This happens because of the damaged myelin around the 
trigeminal nerve nucleus and can result in reduced eating and speaking during these painful 
episodes [69]. Finally, vibration sensation is also affected in people with MS. Decreased 
vibration sensitivity was reported in the lower limbs in ~40% of the patients, while in the 
upper limbs this prevalence increases to ~60% [70].  
Certain sensory symptoms can also arise secondary to the use of medications used in the 
management of MS [54]. For example, the disease modifying therapy interferon beta-1a may 
cause muscle ache, diffuse body pain, worsening spasticity and paraesthesiae that resolve with 
cessation of the drug [53].  
 
Cognitive symptoms 
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Cognitive deficits are reported 40-70% of MS sufferers, with a high incidence in the early 
stages of the disease (Fig. 2) [71]. Cognitive impairments seem to be progressive in nature 
increasing with the level of disability in MS [72,73]. 
Evidence indicates that executive functions (attention, memory and information processing 
cognitive abilities) are impaired in MS, with patients experiencing challenges to the 
performance of activities of daily living as a result [74,75]. Cognitive dysfunction in MS 
manifest itself in deficits in  working memory (i.e. short term memory) [76], verbal (use of 
language) and nonverbal memory (e.g. visual content, auditory information) [77-79],  (visuo-) 
spatial memory (i.e. the ability to navigate in one’s environment based on location of objects 
and oneself) [74,80], in recall and recognition (i.e. retrieve and identify information from past 
memories) [77,78] and in the ability to retain old memories [81,82]. Furthermore, deficits in 
attention [79,80], information processing, decision making and problem solving [81,83,84] 
especially during multitasking activities [85], seem to be frequent. Finally, language and 
verbal fluency are often impaired in MS [75] and these defects manifest in slow speech 
capacity and slow information processing speed [74]. 
Cognitive impairments in MS are extensively associated with lesions and atrophy in the brain 
[86,87] and especially with neocortical grey matter loss [88] and with white matter lesions in 
the corpus callosum that connects the two cerebral hemispheres together [89]. White matter 
lesions associated with cognitive impairment in MS are found in cerebellar peduncle, corona 
radiate, optic radiation, superior longitudinal fasciculus, anterior limb of internal capsule and 
cingulate [90]. Decreased grey matter has been shown for bilateral caudate, left insula and 
right temporal lobe and was related to cognitive deterioration [89]. 
It should be acknowledged that certain aspects of the cognitive symptomatology might be also 
secondary to sleep disorders associated with MS [91]. Abnormal sleep patterns in MS are 
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common (prevalence: ~60% of patients) [91] and can be triggered by sleeping problems such 
as sleep apnea, chronic insomnia disorders and restless leg syndrome [92]. As well as 
contributing to fatigue in MS, sleep disturbances appear to negatively affect cognitive 
functions such concentration, memory, attention and information processing [91, 92].  
Finally, MS medications may also affect patients’ cognitive abilities and thus consideration 
should be given to potential disease-independent changes in cognitive performance when 
administering neuropsychological testing to this patient population. For example, 
anticholinergic drugs may cause cognitive deterioration in attention, processing speed, and 
verbal memory [93]. 
 
Temperature sensitivity in MS 
A unique aspect of MS symptomatology is the highly prevalent temperature sensitivity of its 
sufferers, where neurological symptoms are temporarily exacerbated by environmental- or 
exercise-induced increases (or decreases) in body (core and skin) temperature. 
Heat sensitivity or Uhthoff’s phenomenon occurs in 60-80% of MS patients [1], where 
increases in core body temperature as little as ~0.5oC can trigger temporary symptoms 
worsening. This phenomenon is generally triggered by exposure to warm environment, hot 
baths, or exercise and lasts until core temperature returns to baseline values (36.5 to 37oC) 
[94,95].  However, decreases in body (core and skin) temperature resulting from cold baths or 
exposure to cold ambient temperatures can also trigger a worsening of clinical symptoms 
[96].  
Temperature sensitivity episodes are also known as pseudo-exacerbations or pseudo-relapses.  
While the increase in symptoms may be similar in nature to those experienced during an 
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exacerbation or relapse, the worsening of symptoms is not associated with the disease’s active 
progression and is temporary in nature, with symptoms subsiding upon restoration of core 
temperature. MS patients therefore experience significant challenges in maintaining 
appropriate physical activity levels [97] and conducting normal working activities. Early 
retirement due to heat intolerance and fatigue is highly prevalent amongst MS patients [98]. 
Despite being a frequent complaint in patients with MS, our understanding of how increases 
or decreases in body (core and skin) temperature contribute to transient worsening of MS 
symptoms is incomplete.  
 
Mechanisms of heat sensitivity in MS 
The manifestation of temperature-induced pseudo-exacerbations in MS seems to be primarily 
driven by a transient slowing or blocking of neural conduction within CNS nerve fibres, due 
to core temperature-induced changes in the excitability of demyelinated axons [1,99]. The 
degree of demyelination and the direction (i.e. increases vs. decreases) and magnitude of 
changes in body temperature both contribute to symptoms worsening. As a result, MS patients 
might experience symptoms worsening due to heat or cold sensitivity.   
The effects of increases in core temperature on conduction block have been investigated in 
demyelinated nerve fibres using animal models [57]. For example, Rasminsky (1973) [100] 
investigated the activities between internodes in a demyelinated rat ventral root nerve fibre 
which would fire slower action potentials across the axon in comparison to a myelinated 
nerve fibre. Conduction within the demyelinated nerve fibre was blocked when fibre 
temperature was raised to and beyond 36.5oC. On the contrary conduction was (partially) re-
established when fibre’s temperature was lowered below 36.5oC. In highlighting conduction 
slowing in demyelinated fibres exposed to increased temperatures, this study provided 
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insights on the potential roots of the role of changes in core temperature in the symptoms 
worsening observed in MS patients experiencing heat sensitivity.  
Mechanistically, it would appear that demyelination reduces the axon safety factors, such that 
less current is available to excite nodes of Ranvier and to propagate action potentials 
effectively along the axon (Fig. 1) [1].  Furthermore, there is evidence that segmental axonal 
demyelination in MS unmasks an increased density of membrane potassium channels with a 
high predilection for current leak via potassium efflux with new sodium channels also being 
inserted within the axonal membrane as an ion channel adaptation to demyelination [101]. 
Interestingly, the newly incorporated sodium channels exhibit an altered high sensitivity to 
temperature-induced pore closure, where elevations in temperature of as little as 0.2–0.5°C 
are sufficient to compromise action potential depolarization [101]. The picture that emerges is 
that a combination of changes in the intrinsic excitability of demyelinated fibers and in the 
temperature sensitivity of the ion channels that contribute to their resting membrane 
potentials, result in the conduction slowing and/or block that is typical of Uhthoff’s 
phenomena. 
Such a low temperature threshold (0.2–0.5°C) for compromising action potential 
depolarization within the CNS in MS has been mechanistically confirmed in humans, where 
recent evidence from MS patients with internuclear ophthalmoparesis (i.e. saccadic eye 
disorder) exposed to passive whole-body heating indicated that ocular symptoms worsening 
could occur with increases in core temperature as little as of 0.2°C, and that symptoms 
worsening could be mitigated by restoring core temperature to baseline values via active body 
cooling [102].  
Despite the evidence above, the exact pathophysiology of temperature-dependent conduction 
slowing/blocking in demyelinated axons in MS remains uncertain [103] and consequently, 
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there is still no available pharmacological intervention available that can ameliorate the 
impact of temperature sensitivity on MS patients’ quality of life [104].  
 
Heat-induced worsening of sensory and cognitive MS symptoms 
The majority of experimental studies that have assessed the impact of increases in body (skin 
and core) temperature on MS symptoms worsening have primarily focused on autonomic 
symptoms, with less attention being given to sensory and cognitive symptoms.   
A common approach to the investigation of heat-induced symptoms worsening has been 
based on observations and subjective evaluations of symptoms development during hot baths, 
exercise, exposures to warm ambient temperatures and during seasonal changes. In this 
respect, observations of symptoms worsening during passive heating through hot baths were 
often used in previous decades for the identification of clinical signs in MS [105]. 
With regards to evaluation of sensory symptoms worsening, a recent study attempted to 
characterise how controlled changes in body temperature could affect the skin’ sensitivity to 
thermal stimuli, i.e. thermosensory function. In this study, quantification of afferent 
thermosensory function in RRMS was performed before and after exercise-induced increases 
in patients’ body (cor  and skin) temperature (mean body temperature increase: ~0.4 oC). It 
was found that while the perception of warm stimuli (34oC and 38oC) remained relatively 
similar between pre and post exercise, the perception of cold stimuli (26oC and 22oC) 
decreased in the MS group compared to age-matched heathy controls. This reduced cold 
thermosensitivity was attributed to impaired afferent neural functions within demyelinated 
pathways sub serving cold sensing [106].  
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As a result of the limited mechanistic evidence on how controlled changes in body 
temperature lead to worsening of sensory symptoms, our knowledge on this area mainly relies 
on patients self-reporting symptoms via surveys and questionnaires during warm ambient 
exposures. 
In one such a survey, patients with MS with heat sensitivity reported that they favour staying 
in a room with a temperature of ~20oC. Temperatures higher than the aforementioned were 
indeed associated with higher incidence of experiencing weakness in legs, balance deficits, 
pain, fatigue, spasms, paraesthesia, concentration difficulties and bladder complications [107].  
Similarly to what reported for sensory symptoms, the majority of the evidence on available 
the impact of heat on cognitive function in MS arises from patients’ self-reports and 
observational studies evaluating the impact of outdoor weather on MS symptoms. 
In one such cognitive study involving a cohort of MS patients performing a letter cognitive 
task, functional magnetic resonance imaging (fMRI) was used to show that cognitive 
deterioration in sustained attention and overall thinking was more pronounced as outdoor 
temperatures increased (i.e. from ~ -5oC to ~26oC) [108]. Interestingly, imaging data showed 
that despite warmer outdoor temperatures induced a decline in cognitive performance, some 
brain regions (i.e. frontal gyrus, dorsolateral, prefrontal and parietal lobe areas) appeared to be 
more active in the MS than in the age-gender matched healthy control group. It was suggested 
that reorganizational brain processes might have taken place in the MS group to compensate 
for the damage caused by demyelination [108]. Importantly, and irrespective of any potential 
re-organization, these results indicated that environmental temperature could indeed play a 
role in cognitive symptoms worsening in MS. However, it should be noted that how that may 
occur and what physiological mechanisms might be underlying this were not tested, leaving 
any potential explanation speculative.  
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In a more mechanistic attempt to evaluate cognitive symptoms worsening during heat 
exposure, Hämäläinen et al. [95] recently assessed potential cognitive deterioration in MS 
patients and (age-gender matched) healthy controls performing cognitive tasks during a 25-
min sauna exposure (ambient temperature increasing from ~40oC to ~55oC, with <5% relative 
humidity). As a result of the sauna exposure, MS patients’ core (gastrointestinal) temperature 
increased by ~0.5oC (as compared to a ~0.2 increase in the control group) and these showed 
deteriorated performance in terms of sustained attention, arithmetic calculations, ability to 
focus, information processing speed and flexibility and reaction times in comparison to 
baseline measurements [95].  
The sensory and cognitive studies above seem to provide support to the classic view that 
increases in core temperature of as little as ~0.5oC that would drive heat sensitivity in MS and 
that such mechanisms could impact both sensory and cognitive symptoms (Fig. 3). However, 
it is important to note that very little evidence is available as to whether an increase in core 
temperature is a necessary prerequisite for symptoms worsening to take place, or whether 
changes in skin temperature alone (or in combination with rises in core temperature) can also 
contribute to symptoms worsening. This question is particularly relevant, as anecdotal 
evidence from patients seem to point to the fact that even brief warm ambient exposures as 
well as direct sunlight can trigger symptoms worsening, despite the latter being unlikely to 
drive rises in core temperature. Furthermore, increased exposure to warmer outdoor 
temperatures (likely to induce more frequent rises in skin temperature) seem to be associated 
with higher mortality in MS (at least in the USA), a fact that highlights the importance of 
gathering a better understanding of the underlying mechanisms that lead to heat sensitivity 
[109]. 
A reason why it is reasonable to hypothesise that increases in skin temperature could also 
contribute to heat sensitivity is that in the majority of studies assessing the impact of heat 
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sensitivity in MS, it is common occurrence that rises in core temperature are also 
accompanied by proportional increases in skin temperature. This is an almost unavoidable 
occurrence with some of the heating procedures used, especially when external heat (e.g. 
warm air, hot water) is used to raise internal temperature (as opposed to endogenous heat 
produced via exercise).  
For example, in a recent study people with MS were exposed to moderate heating (passive 
heating) (40oC, 30% RH) in an environmental chamber for 60 min which increased their skin 
temperature ~3.8oC without changes in their core (intestinal) temperature (37.4oC). In that 
experiment, postural sway was found to be increased and posture stability deteriorated after 
short term heat exposure in comparison to an age- and gender-matched healthy control group 
[110]. The motor symptoms that appeared with increased ambient temperatures were 
associated with increases in skin, but not core, temperature in MS. The above claim 
challenges the existing dogma that heat sensitivity only occurs in MS with increases in core 
temperature.  
Recent observations performed with MS patients undergoing passive heat stress accomplished 
via a water-perfused suit, indicated that increases in patients’ core temperature 
(gastrointestinal tract) (~0.6oC) resulted in fatigue perception and impairments in hand motor 
function in comparison to age- and gender- matched healthy group [111]. However, MS 
patients’ skin temperature was also raised during the passive heating protocol (~3.5oC), 
making the independent contribution of core versus skin temperature rises to the development 
of such heat-induced pseudo-exacerbations difficult to isolate. 
Interestingly, further evidence on the role of increases in skin temperature in MS heat 
sensitivity might arise from a hot water immersion study evaluating autonomic and motor 
function in MS. In this study, MS patients reported general body weakness (especially in the 
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extremities), blurring in vision, tachycardia, loss of leg strength and dysarthria (difficulty in 
speaking), as a result of both whole-body immersion (15-34 minutes) in hot water (~40oC-
42oC), as well as during upper or lower limb immersion (17-50 minutes) in hot water (~41oC-
45oC) [112]. As patients’ oral temperature (i.e. a surrogate for core temperature) was observed 
to increase (range: 0.1oC -1.8oC) during whole-body immersion only, the fact that both 
conditions induced a worsening of autonomic and motor performance would point to the 
potential role that an increase in skin temperature only (i.e. during the upper/lower limb 
immersion) could play in triggering heat sensitivity [112]. The age- and gender- matched 
healthy control group did not exhibit any symptoms or signs, such, as weakness, during 
testing. 
It is important to note that the above study focused more on observations than on 
quantifications of heat-induced symptoms. Furthermore, the onset of symptoms in relation to 
changes in core or skin temperature through different time points during the experiment was 
not assessed, thus the independent contribution of rises in skin versus core temperature in the 
development of heat sensitivity in MS requires further mechanistic evaluation.  
Overall, it appears from the analysis above that despite sensory and cognitive symptoms 
representing a significant burden to MS patients’ quality of life, knowledge on how these 
symptoms are impact d by heat sensitivity remains fragmentary.  Furthermore, mechanistic 
evidence about the independent and combined role of increases in internal (core) versus 
external (skin) body temperatures remain ambiguous and require further investigation to 
better elucidate how heat sensitivity is triggered and develops. Finally, the potential 
neuropsychological priming (i.e. placebo effect) produced by a patient’s assumption that heat 
(or cold) exposure might negatively affect their own health should not be underestimated. 
Heightened levels and anxiety in MS patients undergoing environmental heat (or cold) 
exposure could also partly contribute to symptom worsening.   
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Mechanisms of cold sensitivity in MS 
While heat sensitivity seems to be the primary patient complaint in the context of temperature 
sensitivity, cold sensitivity is also reported by MS sufferers (Figure 4).  Twenty percent of 
people with MS experience deterioration of their symptoms during winter and cold ambient 
temperatures, while 5% of the patients report cold sensitivity during cold baths [96]. While 
the incidence rates of cold sensitivity in MS are generally smaller (~15%) than that of heat 
sensitivity [113,114], cold-induced pseudo-exacerbations still play a major role in 
determining patients’ quality of life. 
The primary driver of cold sensitivity in MS seems to be associated with the presence of 
demyelinating lesions within the hypothalamus (i.e. the main CNS area controlling body 
temperature), which result in thermoregulatory dysfunction in the form of blunted autonomic 
responses (i.e. vasoconstriction, shivering) to cold stress [115]. 
The presence of hypothalamic lesions often leads to episodes of hypothermia in MS patients 
[116]. In some extreme cases, core (rectal) temperatures as low as of 29oC have been recorded 
in MS patients presenting demyelinating plaques in the midbrain, pons, medulla, and 
hypothalamus, which eventually led to mortality in the patients [117]. 
It is important to note that while the presence of hypothalamic lesions could affect 
thermoregulatory function and potentially drive cold sensitivity in MS, pseudo-exacerbations 
due to decreases in body temperature per se could still be involved in a worsening of 
symptoms during cold exposures. Yet there is limited evidence as to whether and how 
decreases in body temperature might affect salutatory conduction within CNS demyelinated 
fibres and whether this is analogous to what known with regards to heat sensitivity.  
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Cold-induced worsening of sensory and cognitive MS symptoms 
Cold induced pseudo-exacerbations in MS have been observed and they have been 
subjectively evaluated during weather changes, passive body cooling and cold baths. Yet in 
light of the relatively lower prevalence of cold sensitivity amongst the MS population, most of 
our knowledge on this topic arises from case studies of patients presenting abnormally low 
core temperatures. These case studies can provide insights on the worsening of motor, sensory 
and cognitive symptoms as a result of decreases in body temperature; yet systematic 
investigations of the mechanisms behind cold sensitivity in MS are warranted.   
Amongst those case studies, some stand out for the extent of the decreases in core temperature 
that is observed in some patients, especially when this is compared to the range of normal 
core temperatures observed in resting healthy individuals (i.e. ~36.7-37oC).  
For example, in a MS patient admitted to a medical unit with a few days history of withdrawal 
and lethargy that eventually lapsed into coma, core (rectal) temperature was observed to have 
reached 29oC; following gentle rewarming over 3 days the patient was able to recover, 
although testing after rewarming showed improvements in cognitive function lagged behind 
the re-establishment of normothermia [117]. Interestingly, the same patient presented further 
hypothermic episodes within the following year, suggesting that recurrent thermoregulatory 
dysfunctions in this patient could have been associated with the presence of lesions to 
hypothalamic thermoregulatory centres.  
Further case studies reported that exposure to cold stimuli or to cold weather induced or 
worsened paraesthesia symptoms and vision, and also induced ataxia and vertigo, in MS 
patients [118]. In one of such patients, a worsening of symptoms such as numbness and 
sensation impairments in lower extremities, increased stiffness and walking difficulties and 
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mild spastic paraparesis started to arise with the beginning of the winter season.  The same 
patient was then observed to present worse motor and sensory symptoms during 
psychophysical tests in colder (19oC) than warmer (25oC) ambient room temperatures, as she 
presented lower core (oral) temperatures (36.4oC-36.6oC) under colder conditions. 
Interestingly, the patient’s symptoms improved with body warming that resulted in 
subsequent increases in core temperature [118].  
Another case study showed that exposure to cold weather worsened symptoms and triggered 
difficulties in walking, stiff gait and feeling of falling [118]. When the same patient was 
exposed to cold ambient temperatures (~2oC) in an environmental chamber, this showed 
difficulties in walking, with slow and rigid gait, tremor and uncoordinated upper extremity 
movements, which were further exacerbated and eventually led to spasticity when ambient 
temperature was further lowered [119].  
In a study where MS patients wore a cooling jacket perfusing 10oC water for 2h, an associated 
1oC drop in these patients’ core temperature (tympanic temperature) resulted in slowing down 
patients’ cognitive processes during neuropsychological testing (i.e. attention in auditory 
stimuli, language in word generation, immediate recall and delayed recall for verbal and 
visual memory) but not in the healthy controls (no age-gender matched group) [120].  
Electrophysiological recordings of event-related potentials with the presentation of auditory 
stimuli showed slowed acoustic processing time and deficits in attention processing peak and 
latencies. The cognitive impairments were related to slow conduction velocities in the parts of 
the brainstem that are responsible for auditory evaluation of stimuli [120], a fact which  
suggested a core temperature-dependent mechanisms in the context of cold-induced slowing 
of neural transmission.  
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Altogether, the case studies reviewed above indicate that decreases in core temperature could 
impair sensory and cognitive functions in MS. However, mechanistic evidence on how 
pseudo-exacerbations driven by cold exposures could affect symptoms in MS patients who 
might not present hypothalamic lesions is lacking. Our understanding of the underlying 
physiology of cold sensitivity in MS remains therefore fragmentary. 
Finally, it is important to note that while decreases in body temperature per se might have 
negative effects in some MS patients, body cooling can on the contrary be beneficial to 
dampen the impact of rises in body temperature in heat sensitive patients.  
MS heat-sensitive patients are indeed advised to take advantage of body cooling that can 
decrease their core temperature, especially when it is known that a heat load might be 
experienced (e.g. before doing exercise or being exposed to warm ambient).  
There is broad evidence on the beneficial effect of pre-cooling and per-cooling (i.e. cooling 
during heat exposure) in heat-sensitive patients [121-124]. For example, cold water 
immersion (~21oC-27oC) and related decreases in core temperature (oral temperature) (i.e. 
from ~36.7oC to ~35.5oC) have been shown to improve vision impairment, back pain, 
difficulties in swallowing, spasticity, sensation impairment in lower extremities [125]. 
Similarly, forearm, hand or whole body cooling with cold air exposure in MS have been 
shown to reduce tremor, spasticity symptoms, back pain, and improve vision, speech, and 
exercise performance [113,125,126].  
Finally, a simple method such as cold water ingestion, can also improve exercise tolerance in 
the heat in heat-sensitive MS patients, without any significant change in their core 
temperature (rectal temperature) [127]. 
In the context of the evidence above, it therefore remains to be established how different MS 
patients with different presentations of temperature sensitivity (i.e. heat vs. cold sensitivity) 
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might benefit from different approaches to the manipulation of their body temperature within 
ranges that are optimal for their physiological and cognitive function. 
 
Conclusions and future directions 
MS is a demyelinating disease of the CNS that induces significantly disability due to a variety 
of motor, sensory and cognitive symptoms.  A unique aspect of MS is the highly prevalent 
temperature sensitivity of its sufferers, where neurological symptoms are temporarily 
exacerbated by environmental- or exercise-induced increases (or decreases) in body 
temperature.  
Current evidence suggests that conduction slowing within the CNS due to rises in core 
temperature could trigger exacerbation of sensory and cognitive symptoms, as observed in 
heat sensitive patients; yet only few mechanistic studies are available to confirm such 
hypothesis. As temperature-induced pseudo-exacerbations in MS have been reported to occur 
also without any changes in patients’ core temperature (e.g. during partial body heating or 
sunlight exposure), questions arise as to whether additional factors, such as changes in skin 
temperature, could be involved in the triggering of MS heat-related pseudo-exacerbations. 
Limited knowledge is available on the impact of cold in MS pseudo-exacerbation and related 
sensory and cognitive symptoms, with the majority of evidence arising from case studies of 
hypothermic patients presenting hypothalamic lesions.  
Future research will therefore have to: 1) better elucidate the physiological mechanisms and 
potential triggers of temperature sensitivity; 2) better quantify the extent to which sensory and 
cognitive functions are impacted by rises or drop in body temperature; 3) better determine the 
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impact of cold on symptom worsening in patients who might not present hypothalamic 
lesions.  
The fundamental knowledge arising from the research envisaged above will be useful in 
guiding the design of therapeutic interventions, and of more appropriate working and leisure 
environments, that will ultimately help lifting the burden posed by temperature sensitivity on 
MS patient’s quality of life. 
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Figures 
 
Figure 1.  A schematic overview of a normally myelinated neuron and of a demyelinated 
neuron in MS. While in an unaffected myelinated neuron, saltatory conduction velocities of 
neural inputs are preserved along the axon, in a demyelinated neuron saltatory conduction 
between the Nodes of Ranvier is either slowed or blocked. Demyelination-induced conduction 
slowing/blocking, and related inability for neural signals to be appropriately exchanges 
between neurons, is at the root of MS-related signs and symptoms. 
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Figure 2. Summary of the cognitive, sensory and motor symptoms that have been recorded to 
occur during the course of MS. Cognitive impairments in MS affect executive functions, such 
as deficits in information processing, memory and language. Sensory symptoms constitute an 
uncomfortable subjective experience for the patient when stimuli touch their skin. Altered 
sensations are perceived, such as numbness, burning, pain and pins and needles sensation 
(allodynia, paraesthesia, dysesthesia, trigeminal neuralgia); electrical sensation that moves 
along the spinal cord (Lhermitte’s sign) and decreased vibration experience with the touch of 
a vibrating object on the skin. Motor symptoms include discoordination, tremor and ataxia in 
the limbs which subsequently result in regular falls and fatigue; visual impairments and 
articulation deficits. 
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Figure 3. Summary of symptoms exacerbated by increases in body temperature in MS. Rises 
in body temperature induce: 1) cognitive deficits in attention, concentration and information 
processing; 2) sensory deficits such as altered sensations, body pain, and decreases in 
temperature sensitivity of the skin; 3) motor deficits including spasticity, muscle weakness, 
balance impairments, fatigue and speech difficulties (dysarthria).  All the above symptoms 
have been observed and/or quantified during increases in body temperature in people with 
Multiple Sclerosis. These symptoms are pseudo-exacerbations of ongoing MS symptoms and 
thus, they subside as soon as body temperature is restored to its previous normothermic levels. 
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Figure 4. Summary of symptoms exacerbated by decreases in body temperature in MS. Drops 
in body temperature induce: 1) cognitive deficits in memory, language and attention; 2) 
altered sensations, such as tingling, numbness, burning sensation over the body (paraesthesia), 
and vertigo sensation that results in body imbalance; 3) motor deficits including body 
stiffness, tremor in the extremities, and visual difficulties. These cold-induced pseudo-
exacerbations of symptoms subside as soon as the patient’s body temperature recovers to its 
normothermic levels. 
 
Table 1. MS subtypes, prevalence rates and characteristics
MS subtypes Prevalence in MS population Characteristics 
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Relapsing-Remitting (RRMS) 85% Unpredictable relapses, 
where new symptoms or the 
worsening of previous 
symptoms occur, followed by 
partial or complete recovery. 
The duration of the relapsing 
episodes can last from days 
to months. Incomplete 
recovery from relapse may 
result in residual, persistent 
disability. 
Secondary Progressive 
(SPMS) 
90% of RRMS cases progress 
to SPMS 
Gradual deterioration of 
clinical symptoms that take 
place between or 
irrespective of relapses. 
Most people with MS are 
initially diagnosed with 
RRMS, with a significant 
proportion transitioning to 
SPMS some 10-15 years 
later. MS patients with SPMS 
progress to a disability level 
that is manifested with 
relapse episodes of the MS 
symptoms. 
Primary progressive (PPMS) 10-15% Encounter disability without 
experiencing relapses or 
remissions. 
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